Celsion Corporation  

(Public, NASDAQ:CLSN)   Watch this stock  
Find more results for CLSN
2.52
-0.02 (-0.79%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.41 - 2.60
52 week 2.15 - 3.59
Open 2.60
Vol / Avg. 209,688.00/262,699.00
Mkt cap 58.41M
P/E     -
Div/yield     -
EPS -1.40
Shares 23.00M
Beta 1.49
Inst. own 19%
Aug 11, 2015
Celsion Corp Annual Shareholders Meeting - 4:00AM EDT - Add to calendar
Aug 5, 2015
Q2 2015 Celsion Corp Earnings Release (Estimated) Add to calendar
Jul 8, 2015
Celsion Corp at Cantor Fitzgerald Inaugural Healthcare Conference
May 12, 2015
Q1 2015 Celsion Corp Earnings Call
May 12, 2015
Q1 2015 Celsion Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -5604.06% -5098.85%
Operating margin -5268.30% -4900.25%
EBITD margin - -4592.12%
Return on average assets -44.43% -45.38%
Return on average equity -94.40% -79.24%
Employees 28 -
CDP Score - -

Address

997 Lenox Dr Ste 100
LAWRENCE TOWNSHIP, NJ 08648-2317
United States - Map
+1-609-8969100 (Phone)
+1-609-8962200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Celsion Corporation (Celsion) is an oncology drug development company. The Company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and ribonucleic acid (RNA)- or deoxyribonucleic acid (DNA)-based therapies. Its lead program is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence.

Officers and directors

Jeffrey W. Church CPA Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer
Age: 58
Bio & Compensation  - Reuters
Khursheed Anwer Ph.D. Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
Age: 55
Bio & Compensation  - Reuters
Nicholas Borys M.D. Senior Vice President and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Michael H. Tardugno Executive Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Pok Yu Chow Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Frederick J. Fritz Independent Director
Age: 64
Bio & Compensation  - Reuters
Robert W. Hooper Independent Director
Age: 68
Bio & Compensation  - Reuters
Alberto R. Martinez M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters